MA-EMPATICA/MCROBERTS
13.5.2024 15:00:31 CEST | Business Wire | Press release
Empatica, a pioneer in digital biomarker development and patient monitoring driven by AI, and McRoberts, one of the leaders in ambulatory monitoring of physical activity, announce the integration of all 71 McRoberts endpoints in Empatica’s digital biomarkers portfolio and FDA-cleared platform, bringing its total offering to over 200.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513976022/en/
The FDA-cleared Empatica Health Monitoring Platform will host all 71 McRoberts endpoints, which will be monitored using Empatica's EmbracePlus wearable. With a modular design, it can be worn on the wrist, waist, hip and other locations on the body, providing a range of versatile digital health measures. (Graphic: Business Wire)
The additional digital biomarkers will enhance the Empatica Health Monitoring Platform with new measures in categories including activity monitoring, energy expenditure, and sleep movements, and introduce key Functional Mobility Assessments such as the sit-to-stand test, gait test, timed up & go test, sway test, and stair test, which play a crucial role in assessing physical function and mobility in clinical care and research settings.
“This partnership shows a maturing digital health industry,” said Matteo Lai, Empatica’s CEO and Co-Founder. “Established players are joining forces to provide a one-stop solution to sponsors across the world. You can get the best medical technology and validated measures with a long clinical history in the same place: this means less setup time, costs and patient burden.”
“We are delighted to share the news of our partnership with Empatica,” said Martijn Niessen, CEO at McRoberts. “Combining our mobility analytics with their versatile platform and extensive array of physiological and behavioral biomarkers promises immense benefits for both our customers.”
The partnership cements the Empatica Health Monitoring Platform’s ability to be fully compatible with validated third-party algorithms. It is also the first known instance where an already established provider moves from using their proprietary wearable to a different device platform, allowing them to focus more energies on developing new endpoints. This showcases the confidence placed in Empatica’s technology, particularly in the monitoring capabilities of the EmbracePlus wearable. It also paves the path to additional partnerships, making it a true platform for other digital biomarker developers to have algorithms implemented in large-scale initiatives without needing to worry about the development of dedicated hardware and compatible software.
The McRoberts algorithms are available to all Enterprise plan users of the Empatica Health Monitoring Platform. Visit Empatica’s website to find out more, or reach out directly to Empatica at research@empatica.com.
About Empatica
Empatica Inc is a pioneer in continuous, unobtrusive remote health monitoring driven by AI. Empatica's FDA-cleared platform and technology are used by thousands of institutional partners for research purposes, in studies examining stress, sleep, epilepsy, migraine, depression, addiction, and other conditions. Its flagship medical wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and the NASA-funded TRISH.
About McRoberts
McRoberts specializes in providing comprehensive solutions for assessing human mobility both in daily life and laboratory settings. McRoberts introduced its first algorithm and wearable sensor system for activity monitoring in 1994. Since then, their MoveMonitor and MoveTest solutions have been extensively utilized in clinical trials, healthcare, and academic research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513976022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom